Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B

Journal of Drug Targeting

Volumn 13, Issue 4, 2005, Pages 225-233

  Sanchez Brunete J A ^a   Dea, M A ^a   Rama, S ^a   Bolas F ^a   Alunda, J M ^b   Torrado Santiago, S ^a   Torrado, J J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Albumin microspheres; Amphotericin B; Dispersability; Microparticles

Indexed keywords

ACID ANHYDRIDE; ALBUMIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; DRUG CARRIER; DRUG VEHICLE; MICROSPHERE; POLYANHYDRIDE; POLYGLACTIN; RESOMER; SEBACIC ACID; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIPROTOZOAL ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFICACY; DRUG MANUFACTURE; HAMSTER; HEATING; HIGH TEMPERATURE; IN VIVO STUDY; LEISHMANIA INFANTUM; LEISHMANIASIS; LIVER PARENCHYMA; MALE; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SPLEEN; SPRAY DRYING; TREATMENT OUTCOME;

ALBUMINS; AMPHOTERICIN B; ANIMALS; ANTIGENS, PROTOZOAN; ANTIPROTOZOAL AGENTS; CRICETINAE; DRUG CARRIERS; DRUG COMPOUNDING; LACTIC ACID; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LIVER; MALE; MESOCRICETUS; MICROSPHERES; PARTICLE SIZE; POLYANHYDRIDES; POLYGLYCOLIC ACID; POLYMERS; SPLEEN;

EID: 23144440576     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/10611860500097107     Document Type: Article

References (44)

1. Allémann E, Gurny R, Leroux JC. 1998. Biodegradable nano-particles of poly(lactic acid) and poly(lactic-co-glycolic acid) for parenteral administration. Pharmaceutical dosage forms: Disperse systems. Vol. 3. 2nd ed. Marcel Dekker Inc.
2. Benelli P, Conti B, Genta I, Constantini M, Montanari L. 1998. Clonazepam microencapsulation in poly-D,L-lactide-co-glycolide microspheres. J Microencapsul 15:431-443.
3. Berman JD. 1997. Human leishmaniosis: Clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684-703.
4. Bittner B, Kissel T. 1999a. Ultrasonic atomization for spray drying: A versatile technique for the preparation of protein loaded biodegradable microspheres. J Microencapsul 16:325-341.
5. Bittner B, Mader K, Kroll C, Borchert HH, Kissel T. 1999b. Tetracycline-HCl-loaded poly (DL-lactide-co-glycolide) microspheres prepared by a spray drying technique: influence of gamma-irradiation on radical formation and polymer degradation. J Control Rel 59:23-32.
6. Blanco-Prieto MJ, Besseghir K, Zerbe O, Andris D, Orsolini P, Heimgartner F, Merkle HP, Gander B. 2000. In vivo and in vitro evaluation of a somatostatin analogue released from PLGA microspheres. J Control Rel 67:19-28.
7. Brajtburg J, Elberg S, Kobayashi GS, Bolard J. 1994. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: Molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Antimicrob Agents Chemother 38:300-306.
8. Brophy MR, Deasy PB. 1988. Biodegradable polyester polymers as drug carriers. Encyclopedia of pharmaceutical technology. Vol. 2. 1st ed. Marcel Dekker Inc.
9. Dang W, Daviau T, Brem H. 1996. Morphological characterization of polyanhydride biodegradable implant gliadel during in vitro and in vivo erosion using scanning electron microscopy. Pharm Res 13:683-691.
10. Deng JS, Li L, Tian Y, Meisters M, Chang HC, Stephens D, Chen S, Robinson D. 2001. The relationship between structures and in vitro properties of a polyanhydride implant containing gentamicin sulphate. Pharm Dev Technol 6:541-549.
11. Ernst C, Grange J. 1981. Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies. Biopolymers 20:1575-1588.
12. García del Barrio G, Novo FJ, Irache JM. 2003. Loading of plasmid DNA into PLGA microparticles using TROMS (Total Recirculation One-Machine System): Evaluation of its integrity and controlled release properties. J Control Rel 86:123-130.
13. Giunchedi P, Conti B, Genta I, Conte U, Puglisi G. 2001. Emulsion spray-drying for the preparation of albumin-loaded PLGA microspheres. Drug Dev Ind Pharm 27:745-750.
14. Hill JO, North RJ, Collins FM. 1983. Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect Immun 39:1087-1094.
15. Johansen P, Tamber H, Merkle HP, Gander B. 1999. Diphtheria and tetanus toxoid microencapsulation into conventional and end-group alkylated PLA/PLGAs. Eur J Pharm Biopharm 47:193-201.
16. Johansen P, Estévez E, Zurbriggen R, Merkle HP, Gluck R, Corradin G, Gander B. 2000. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19:1047-1054.
17. Katjár M, Vikmon K, Morlin E, Szejtli J. 1989. Aggregation of amphotericin B in the presence of Γ-cyclodextrin. Biopolymers 28:1585-1586.
18. Kipper MJ, Shen E, Determan A, Narasimhan B. 2002. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. Biomaterials 23:4405-4412.
19. Lacasse FX, Filion MC, Phillips NC, Escher E, McMullen JN, Hildgen P. 1998. Influence of surface properties at biodegradable microsphere surfaces: Effects on plasma protein adsorption and phagocytosis. Pharm Res 15:312-317.
20. Legrand P, Cheron M, Leroy L, Bolard J. 1997. Release of amphotericin B from delivery systems and its action against fungal and mammalian cells. J Drug Target 4:311-319.
21. Leong KW, Kost J, Mathiowitz E, Langer R. 1986. Polyanhydrides for controlled release of bioactive agents. Biomaterials 7:364-371.
22. Mohr D, Wolff M, Kissel T. 1999. Gamma radiation for terminal sterilization of 17beta-estradiol loaded poly-(D,L-lactide-co-glycolide) microparticles. J Control Rel 61:203-217.
23. Mu L, Feng SS. 2001. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Rel 76:239-254.
24. Mullen AB, Carter KC, Baillie AJ. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniosis. Antimicrob Agents Chemother 41:2089-2092.
25. Murillo M, Gamazo C, Goñi MM, Irache JM, Blanco-Prieto MJ. 2002a. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis. Int J Pharm 242:341-344.
26. Murillo M, Goñi MM, Irache JM, Arangoa MA, Blasco JM, Gamazo C. 2002b. Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens. J Control Rel 85:237-246.
27. Nelson CL, Hickmon SG, Skinner RA. 1997. Treatment of experimental osteomyelitis by surgical debridement and the implantation of bioerodable, polyanhydride-gentamicin beads. J Orthop Res 15:249-255.
28. O'Hara P, Hickey AJ. 2000. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Manufacture and characterization. Pharm Res 17:955-961.
29. Pavanetto F, Genta I, Giunchedi P, Conti B. 1993. Evaluation of spray drying as a method for polylactide and polylactide-co-glycolide microsphere preparation. J Microencapsul 10:487-497.
30. Prior S, Gamazo C, Irache JM, Merkle HP, Gander B. 2000. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections. Int J Pharm 196:115-125.
31. Prior S, Gander B, Blarer N, Merkle HP, Subirá ML, Irache JM, Gamazo C. 2002. In vivo phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur J Pharm Sci 15:197-207.
32. Rex JH, Walsh TJ. 1999. Estimating the true cost of amphotericin B. Clin Infect Dis 29:1408-1410.
33. Sánchez-Brunete JA, Dea MA, Rama S, Bolás F, Alunda JM, Raposo R, Méndez MT, Torrado-Santiago, Torrado JJ. 2004a. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 48:3246-3252.
34. Sánchez-Brunete JA, Dea MA, Rama S, Bolás F, Alunda JM, Torrado-Santiago, Torrado JJ. 2004b. Amphotericin B molecular organization as an essential factor to improve activity/toxicity ratio in the treatment of visceral leishmaniasis. J Drug Target 12:453-460.
35. Tabata Y, Ikada Y. 1991. Phagocytosis of polymeric microspheres. In: Szycher M, editor. High performance biomaterials. Lancaster: Technomic Publishing. p 621-646.
36. Tabata Y, Langer R. 1993b. Polyanhydride microspheres that display near-constant release of water-soluble model drug compounds. Pharm Res 10:391-399.
37. Tabata Y, Gutta S, Langer R. 1993a. Controlled delivery systems for proteins using polyanhydride microspheres. Pharm Res 10:487-496.
38. Takada S, Uda Y, Toguchi H, Ogawa Y. 1995. Application of a spray drying technique in the production of THR-containing injectable sustained-release microparticles of biodegradable polymers. PDA J Pharm Sci Technol 49:180-184.
39. Thombre AG, Cardinal JR. 1988. Biopolymers for controlled drug delivery Encyclopedia of pharmaceutical technology. Vol 2. 1st ed. Marcel Dekker Inc.
40. Titus RG, Marchand M, Boon T, Louis JA. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol 7:545-555.
41. Wagenaar BW, Muller BW. 1994. Piroxicam release from spray-dried biodegradable microspheres. Biomaterials 15:49-54.
42. Walter E, Dreher D, Kok M, Thiele L, Kiama SG, Gehr P, Merkle HP. 2001. Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J Control Rel 76:149-168.
43. Wong-Beringer A, Jacobs RA, Guglielmo BJ. 1998. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 27:603-618.
44. Yang Z, Birkenhauer P, Julmy F, Chickering D, Ranieri JP, Merkle HPT, Luscher TF, Gander B. 1999. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J Control Rel 60:269-277.